Context
Primary aldosteronism (PA) is associated with impaired quality of life (QoL). Autonomous cortisol co-secretion (ACS) is a relevant phenotype of PA, which could contribute to depression and anxiety disorders. This has not been investigated so far.
Objective
To evaluate the prevalence of depression and anxiety in PA patients according to ACS.
Methods
We performed testing for hypercortisolism and evaluated anxiety, depression and QoL by self-rating questionnaires in newly diagnosed PA patients of the German Conn´s Registry; 298 patients were reevaluated at follow-up.
Results
In the overall cohort, scores for anxiety (p<0.001), depression (p<0.001), and QoL (mental p=0.021; physical p=0.015) improved significantly at follow-up. This improvement was seen in both subgroups of patients with and without ACS, with the exception of the mental subscore in no-ACS patients. Analysis for sex differences showed that anxiety decreased significantly in females with ACS and no-ACS, whereas males with no-ACS failed to improve. Depression improved significantly in males and females with ACS (p=0.004, p=0.011 respectively), but not in those with no-ACS. Physical subscore of QoL improved significantly (p=0.023) in females with ACS and mental subscore (p=0.027) in males with ACS, whereas no differences were seen for the no-ACS groups.
Conclusion
Improvement in depression and anxiety scores in response to treatment of PA is more pronounced in patients with ACS in contrast to no-ACS suggesting a role of ACS in the psychopathological symptoms of patients with PA. Furthermore, we observed significant differences in depression and anxiety scores between the sexes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.